PYC Therapeutics H1 2026 Losses Highlight Ongoing Investment And Test Bullish Profitability Narrative

Simply Wall St.

Feb 24

PYC Therapeutics (ASX:PYC) has reported its H1 2026 numbers with trailing twelve month revenue of A$21.8 million and a basic EPS loss of A$0.085, indicating that the business is still investing ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2613715809"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613715809\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613715809?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-24 17:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613715809","market":"sg","top_or_hot":-1,"title":"PYC Therapeutics H1 2026 Losses Highlight Ongoing Investment And Test Bullish Profitability Narrative","media":"Simply Wall St.","content":"<div>\n<p>PYC Therapeutics (ASX:PYC) has reported its H1 2026 numbers with trailing twelve month revenue of A$21.8 million and a basic EPS loss of A$0.085, indicating that the business is still investing ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-h1-2026-losses-highlight-ongoing-investment\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PYC Therapeutics H1 2026 Losses Highlight Ongoing Investment And Test Bullish Profitability Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPYC Therapeutics H1 2026 Losses Highlight Ongoing Investment And Test Bullish Profitability Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-24 17:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-h1-2026-losses-highlight-ongoing-investment><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PYC Therapeutics (ASX:PYC) has reported its H1 2026 numbers with trailing twelve month revenue of A$21.8 million and a basic EPS loss of A$0.085, indicating that the business is still investing ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-h1-2026-losses-highlight-ongoing-investment\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLSG","symbol_name":"2倍做多BLSH ETF-Leverage Shares","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-h1-2026-losses-highlight-ongoing-investment","article_id":"2613715809","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-h1-2026-losses-highlight-ongoing-investment","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2613715809","pubTimestamp":1771925358,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"PYC Therapeutics (ASX:PYC) has reported its H1 2026 numbers with trailing twelve month revenue of A$21.8 million and a basic EPS loss of A$0.085, indicating that the business is still investing heavily to progress its pipeline. Over recent reporting periods, revenue has moved from A$13.2 million in H2 2024 to A$11.8 million in H1 2025 and A$11.7 million in H2 2025, while basic EPS losses have shifted from A$0.055 in H2 2024 to A$0.0548 in H1 2025 and A$0.046 in H2 2025. This gives investors a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLSG":"2倍做多BLSH ETF-Leverage Shares","BK7067":"生物科技","PYC.AU":"PYC THERAPEUTICS LTD","BK4007":"制药","BK4112":"金融交易所和数据","BK4539":"次新股","BLSX":"Tradr 2X Long BLSH Daily ETF","BK4139":"生物科技"},"translate_title":"PYC Therapeutics 2026年上半年亏损凸显持续投资并测试看涨盈利能力叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLSG":0.6,"BLSX":0.6,"PYC.AU":1.96},"content_text":"PYC Therapeutics (ASX:PYC) has reported its H1 2026 numbers with trailing twelve month revenue of A$21.8 million and a basic EPS loss of A$0.085, indicating that the business is still investing heavily to progress its pipeline. Over recent reporting periods, revenue has moved from A$13.2 million in H2 2024 to A$11.8 million in H1 2025 and A$11.7 million in H2 2025, while basic EPS losses have shifted from A$0.055 in H2 2024 to A$0.0548 in H1 2025 and A$0.046 in H2 2025. This gives investors a clearer view of how much it is costing to generate that top line. With analysts expecting strong earnings growth and a path to profitability over the next few years, this set of results focuses attention on how quickly margins might tighten from here. See our full analysis for PYC Therapeutics. With the headline numbers in place, the next step is to see how they line up against the dominant market narratives around PYC, highlighting where the story is supported by the data and where expectations might need to be reconsidered. Curious how numbers become stories that shape markets? Explore Community Narratives ASX:PYC Earnings & Revenue History as at Feb 2026 AdvertisementTTM loss of A$47.6 million keeps PYC firmly in investment mode  Over the trailing twelve months to H1 2026, PYC recorded total revenue of A$21.8 million and a net loss of A$47.6 million, compared with a net loss of A$50.3 million on A$23.5 million of revenue for the prior trailing period. For investors taking a bullish view, analysts are expecting earnings to grow about 47.77% per year and for PYC to become profitable within three years, while:\n     Recent half yearly net losses of A$25.6 million in H1 2025 and A$24.7 million in H2 2025 show the business is still loss making even as the earnings outlook improves on paper. Basic EPS on a trailing basis was a loss of A$0.085 per share in H1 2026 compared with a trailing loss of A$0.11 per share in early 2025, so the earnings forecast has to be weighed against the fact that the company is still generating sizeable accounting losses today.    Revenues steady while future forecasts point to a 5.1% annual decline  Over the last three reported half years, revenue has sat in a relatively tight band between A$11.7 million and A$13.2 million. In contrast, analysts expect revenue to decline around 5.1% per year over the next three years. That expectation challenges a simple bullish story that higher earnings must come from higher sales, because:\n     The trailing revenue line of A$21.8 million in H1 2026 is already below the prior trailing figure of A$25.0 million reported for H1 2025, which lines up with the view that top line may soften rather than expand. If earnings do improve while revenue drifts from the A$11.7 million to A$13.2 million half yearly range, the improvement would have to come from cost discipline or mix rather than volume growth, and the current numbers do not yet show that turn in the income statement.    High 9.5x P/B multiple and recent dilution set a high bar  PYC is trading around A$1.49 per share with a P/B of 9.5x, compared with 3.7x for peers and 5.7x for the wider Australian biotech group, and shareholders have also experienced substantial dilution over the past year. Critics highlight that this combination of a richer P/B and dilution makes execution on the earnings turnaround especially important, because:\n     The trailing net loss of A$47.6 million and basic EPS loss of A$0.085 over the last twelve months mean book value is being used to support a relatively full valuation while the business is still firmly pre profit. With losses having grown about 29.2% per year over the past five years, the current A$1.49 share price and 9.5x P/B ratio leave less room for error if the forecast path to profitability within three years does not materialise as expected.    Curious how this mix of losses, forecasts and valuation is shaping the broader story around PYC? 📊 Read the what the Community is saying about PYC Therapeutics. Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on PYC Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. If this mix of optimism and concern around PYC leaves you on the fence, move quickly to review the underlying data and stress test your own thesis. You can start with our breakdown of 1 key reward and 1 important warning sign. Explore Alternatives PYC is still reporting sizeable losses, relatively flat revenue and a richer 9.5x P/B multiple, which together leave limited room for execution missteps. If that mix of ongoing losses and a full looking valuation feels uncomfortable, shift some attention to our 6 resilient stocks with low risk scores to quickly shortlist companies with more resilient profiles.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}